Mental Health Research Briefing — 2026-07-16

Key Research Findings

Depression Impacts All Five Senses—New Diagnostic Breakthrough

• Published in: Medical research (University of New England study)
• What they found: A new study led by Professor Christopher Sharpley of the University of New England's Department of Neuroscience examined how depression affects sensory perception across sight, sound, smell, taste, and touch. The research confirms that depression produces measurable changes in all five sensory systems, not just mood and cognition.
• Why it matters: This discovery could significantly improve diagnosis and enable more targeted treatments. If sensory impairment becomes a diagnostic marker for depression, clinicians may catch the condition earlier and tailor interventions to address the specific sensory deficits patients experience, opening doors to more personalized therapeutic approaches.
• Sample/Method: Peer-reviewed neuroscience research examining sensory perception in depression

Prucalopride (Constipation Medication) Clears Depression Brain Fog in Clinical Trial

• Published in: ScienceDaily
• What they found: In a small clinical trial, people with a history of depression who took prucalopride for about one week performed significantly better on tests of memory, attention, and thinking speed compared to those receiving placebo. The medication, commonly used to treat constipation, demonstrated unexpected cognitive benefits in depressed patients.
• Why it matters: This finding could lead to rapid repurposing of existing, FDA-approved drugs for depression-related cognitive dysfunction—a frequent and debilitating symptom that current antidepressants often fail to address. If validated in larger trials, prucalopride could offer a low-risk option for patients struggling with brain fog.
• Sample/Method: Small clinical trial with placebo control group; cognitive testing on memory, attention, and processing speed

3 sources

sciencedaily.com

Mental Health Research News -- ScienceDaily

sciencedaily.com

Common constipation drug may help clear depression brain fog | ScienceDaily

sciencedaily.com

Mental Health News -- ScienceDaily

Climate Change Quantified as Major Mental Health Threat Across Multiple Countries

• Published in: News Medical
• What they found: A new study has, for the first time, quantitatively projected how climate change will affect mental health at a multi-country level. The research moves beyond qualitative concern to hard numbers, modeling the mental health burden expected as global temperatures rise.
• Why it matters: This is the first quantitative, multi-country model of climate change's mental health impact. Policymakers now have data to justify climate-mental health policy integration. The findings underscore that climate action is mental health action, and could drive investment in both climate mitigation and mental health services in vulnerable populations.
• Sample/Method: Multi-country quantitative projection modeling

1 sources

news-medical.net

news-medical.net

Online Time Matters, But What Happens Online Matters More: Gender-Stratified Analysis

• Published in: Medical Xpress
• What they found: A large college-based study examined how time spent online and the types of experiences that occur online relate to mental health outcomes. The research found that both duration and the quality of online experiences matter, with significant differences across gender identities—an understudied area in prior research.
• Why it matters: This nuanced finding challenges simplistic "screen time is bad" narratives and highlights the need for targeted interventions. Different gender-identity groups may need different digital wellness strategies. The research addresses a major gap: most large-scale studies have not examined gender-stratified impacts of online activity on mental health.
• Sample/Method: Large-scale, multisite college sample with gender-identity stratification

Clinical & Treatment Updates

• Centanafadine (Triple Monoamine Reuptake Inhibitor) Shows Promise Across Age Groups: Centanafadine, a norepinephrine-dopamine-serotonin reuptake inhibitor, demonstrated symptom improvements across 4 phase 3 trials spanning pediatric, adolescent, and adult populations. This triple-action mechanism may address symptoms that current single-pathway medications miss, offering hope for treatment-resistant cases across the lifespan.

• HHS and VA Announce Partnership for Rapid-Acting Mental Health Treatments: The U.S. Department of Health and Human Services and the Department of Veterans Affairs entered into a Memorandum of Understanding to strengthen collaboration on research, clinical development, and responsible deployment of rapid-acting mental health treatments to veterans suffering from serious mental health conditions. This high-level federal commitment signals accelerated psychedelic therapy research and deployment timelines.

Policy & Society

• Heat Extremes Double Young People's Mental Health Hospital Admissions: Exclusive University of Sydney research shows that extreme high temperatures increase mental health-related hospital admissions in young people by at least 6% by the end of the century. This Australian finding directly links climate extremes to acute psychiatric crisis, reinforcing the urgency of climate-adapted mental health infrastructure in vulnerable regions.

• Psychologist Candice Odgers Challenges Social Media Ban Narrative: In a Guardian feature published today, prominent psychologist and 25-year adolescent mental health researcher Candice Odgers cautions against oversimplifying the youth mental health crisis to smartphone use alone. She argues that major drivers—including COVID-19 impacts and adult caregiver mental health—are being obscured by the current debate, urging a more nuanced, evidence-based policy approach.

Expert Perspectives

This week's research reveals a fundamental shift in mental health understanding: from a purely psychological/neurochemical model toward an integrated bio-sensory-environmental framework. The depression-sensory findings suggest that clinicians should assess sensory dysfunction as a core feature of depression, not a secondary symptom. Simultaneously, the prucalopride discovery demonstrates that the gut-brain connection remains fertile ground for rapid drug repositioning—existing medications may hold unexpected mental health benefits. Most critically, the climate-mental health quantification and heat-admission data signal that mental health cannot be decoupled from environmental and planetary health. For policymakers, these findings converge on one message: mental health interventions must be personalized (sensory-informed), biologically creative (gut-based treatments), and climate-conscious. Psychologist Candice Odgers's caution against oversimplifying youth mental health to screen time alone echoes across the data—context, lived experience, and systemic stressors matter as much as technology exposure.

What to Watch

• Prucalopride larger clinical trials: Watch for phase 2/3 expansion of prucalopride in depression-related cognitive impairment; approval could create a new treatment class for brain fog—one of psychiatry's most treatment-resistant symptoms.
• HHS-VA psychedelic therapy deployment: Timeline and outcomes from the newly announced federal partnership on rapid-acting mental health treatments for veterans; this could accelerate FDA approval of psilocybin and other psychedelics for PTSD and treatment-resistant depression.
• Climate-mental health policy integration: Upcoming WHO and national government responses to the multi-country climate-mental health quantification; expect new funding streams and infrastructure planning linking climate adaptation to psychiatric capacity-building, especially in vulnerable regions facing heat extremes.